Twelve weeks of exenatide treatment increases [¹⁸F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.

Janssen LGM, Nahon KJ, Bracké KFM, van den Broek D, Smit R, Sardjoe Mishre ASD, Koorneef LL, Martinez-Tellez B, Burakiewicz J, Kan HE, van Velden FHP, Pereira Arias-Bouda LM and 5 more

Show all authors

de Geus-Oei LF, Berbée JFP, Jazet IM, Boon MR, Rensen PCN

Metabolism: clinical and experimental23 Jan 2020Cited by 47 (Europe PMC)

PMID31982480DOI10.1016/j.metabol.2020.154167PepBankPUB-31982480

Read at source PubMedAsk about this study

Jump to 10 results

Summary

Aims/hypothesisBrown adipose tissue (BAT) improves energy metabolism by combusting glucose and lipids into heat. Agonism of the glucagon-like peptide-1 receptor (GLP-1R) within the central nervous system activates BAT in mice. Moreover, in patients with type 2 diabetes, GLP-1R agonism lowers body weight and improves glucose and lipid levels, possibly involving BAT activation. Interestingly, people from South Asian descent are prone to develop cardiometabolic disease. We studied the effect of GLP-1R agonism on BAT in humans, specifically in South Asians and Europids without obesity or type 2 diabetes.MethodsTwelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study. Before and after treatment, BAT was visualized by a cold-induced [¹⁸F]FDG-PET/CT scan and a thermoneutral MRI scan, and resting energy expenditure (REE), substrate oxidation, body composition and fasting plasma glucose and serum lipids were determined. Appetite was rated using a visual analogue scale.ResultsSince the effect of exenatide on metabolic parameters did not evidently differ between ethnicities, data of all participants were pooled. Exenatide decreased body weight (-1.5 ± 0.4 kg, p < 0.01), without affecting REE or substrate oxidation, and transiently decreased appetite ratings during the first weeks. Exenatide also lowered triglycerides (-15%, p < 0.05) and total cholesterol (-5%, p < 0.05), and tended to lower glucose levels. Notably, exenatide increased BAT metabolic volume (+28%, p 18F]FDG-PET/CT), without affecting supraclavicular adipose tissue fat fraction (MRI).Conclusions/interpretationWe show for the first time that GLP-1R agonism increases [¹⁸F]FDG uptake by BAT in South Asian and Europid men without obesity or type 2 diabetes.Trial registryClinicaltrials.gov NCT03002675.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide decreased body weight from baseline.
In plain wordsIn nondiabetic men, exenatide reduced weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Weight change
−1.5 kg
from baseline
Source sentences
Summary
Exenatide decreased body weight (-1.5 ± 0.4 kg, p < 0.01), without affecting REE or substrate oxidation, and transiently decreased appetite ratings during the first weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248001
02HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide did not affect resting energy expenditure.
In plain wordsIn nondiabetic men, resting energy use did not change from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeResting energy expenditure
Study
n = 24
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide decreased body weight (-1.5 ± 0.4 kg, p < 0.01), without affecting REE or substrate oxidation, and transiently decreased appetite ratings during the first weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248002
03HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide did not affect substrate oxidation.
In plain wordsIn nondiabetic men, substrate oxidation did not change from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSubstrate oxidation
Study
n = 24
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide decreased body weight (-1.5 ± 0.4 kg, p < 0.01), without affecting REE or substrate oxidation, and transiently decreased appetite ratings during the first weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248003
04HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide transiently decreased appetite ratings during the first weeks.
In plain wordsIn nondiabetic men, appetite temporarily decreased from baseline during the first weeks of exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAppetite ratings
Study
n = 24
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide decreased body weight (-1.5 ± 0.4 kg, p < 0.01), without affecting REE or substrate oxidation, and transiently decreased appetite ratings during the first weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248004
05HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide lowered triglycerides.
In plain wordsIn nondiabetic men, triglycerides decreased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides
Study
n = 24
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Triglyceride change
−15%
from baseline
Source sentences
Summary
Exenatide also lowered triglycerides (-15%, p < 0.05) and total cholesterol (-5%, p < 0.05), and tended to lower glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248005
06HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide lowered total cholesterol.
In plain wordsIn nondiabetic men, total cholesterol decreased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal cholesterol
Study
n = 24
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Total cholesterol change
−5%
from baseline
Source sentences
Summary
Exenatide also lowered triglycerides (-15%, p < 0.05) and total cholesterol (-5%, p < 0.05), and tended to lower glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248006
07HumanNon-randomized trialEfficacy outcome
In nondiabetic men, glucose levels tended to decrease with exenatide, without a reported significant change.
In plain wordsIn nondiabetic men, glucose levels tended to fall from baseline during exenatide treatment, with no significant change reported.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlucose
Study
n = 24
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Exenatide also lowered triglycerides (-15%, p < 0.05) and total cholesterol (-5%, p < 0.05), and tended to lower glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248007
08HumanNon-randomized trialActivity measurement
In nondiabetic men, exenatide increased brown adipose tissue metabolic volume.
In plain wordsIn nondiabetic men, brown fat metabolic volume increased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBAT metabolic volume
Study
n = 24
Outcome group
Fat metabolism and adipogenesis · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
BAT metabolic volume change
28%
from baseline
Source sentences
Summary
Notably, exenatide increased BAT metabolic volume (+28%, p 18F]FDG-PET/CT), without affecting supraclavicular adipose tissue fat fraction (MRI).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248008
09HumanNon-randomized trialActivity measurement
In nondiabetic men, exenatide increased mean standardized FDG uptake in brown adipose tissue.
In plain wordsIn nondiabetic men, measured glucose tracer uptake in brown fat increased from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBAT mean standardized uptake value
Study
n = 24
Outcome group
Fat metabolism and adipogenesis · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Mean standardized uptake value change
11%
from baseline
Source sentences
Summary
Notably, exenatide increased BAT metabolic volume (+28%, p 18F]FDG-PET/CT), without affecting supraclavicular adipose tissue fat fraction (MRI).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248009
10HumanNon-randomized trialEfficacy outcome
In nondiabetic men, exenatide did not affect supraclavicular adipose tissue fat fraction.
In plain wordsIn nondiabetic men, supraclavicular tissue fat fraction did not change from baseline during exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSupraclavicular adipose tissue fat fraction
Study
n = 24
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Notably, exenatide increased BAT metabolic volume (+28%, p 18F]FDG-PET/CT), without affecting supraclavicular adipose tissue fat fraction (MRI).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve Dutch South Asian and 12 age- and BMI-matched Europid nondiabetic men received 12 weeks extended-release exenatide (Bydureon) in this single-arm prospective study.
Show in the study text Report a problemFND-3198248010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT03002675

Exenatide and Brown Adipose Tissue

Ingrid Jazetn = 24Aug 2016 to est. Jun 2018 (primary)

Obesity

Trial page ClinicalTrials.govUpdated 26 Dec 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.